The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database.
Saved in:
| Title: | The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database. |
|---|---|
| Authors: | Sengupta, Chandrima1 (AUTHOR) Chandrima.Sengupta@sydney.edu.au, Nguyen, Doan Trang1 (AUTHOR), Li, Yifan1 (AUTHOR), Hewson, Emily1 (AUTHOR), Ball, Helen1 (AUTHOR), O'Brien, Ricky1,2 (AUTHOR), Booth, Jeremy3 (AUTHOR), Kipritidis, John3 (AUTHOR), Eade, Thomas3 (AUTHOR), Kneebone, Andrew3 (AUTHOR), Hruby, George3 (AUTHOR), Bromley, Regina3 (AUTHOR), Greer, Peter4 (AUTHOR), Martin, Jarad4 (AUTHOR), Hunter, Perry4 (AUTHOR), Wilton, Lee4 (AUTHOR), Moodie, Trevor5 (AUTHOR), Hayden, Amy5 (AUTHOR), Turner, Sandra5 (AUTHOR), Hardcastle, Nicholas6 (AUTHOR) |
| Source: | Medical Physics. Mar2025, Vol. 52 Issue 3, p1941-1949. 9p. |
| Subjects: | Stereotactic radiotherapy, Prostate cancer, Clinical trials, Image-guided radiation therapy, Treatment effectiveness, Medical research, Radiotherapy |
| Abstract: | Purpose: The US National Institutes of Health state that Sharing of clinical trial data has great potential to accelerate scientific progress and ultimately improve public health by generating better evidence on the safety and effectiveness of therapies for patients (https://www.ncbi.nlm.nih.gov/books/NBK285999/ accessed 2024‐01‐24.). Aligned with this initiative, the Trial Management Committee of the Trans‐Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM) (SPARK) clinical trial supported the public sharing of the clinical trial data. Acquisition and Validation Methods: The data originate from the TROG 15.01 SPARK clinical trial. The SPARK trial was a phase II prospective multi‐institutional clinical trial (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real‐time image‐guided radiotherapy technology named KIM for 48 prostate cancer patients treated in 5 treatment sessions. During treatment, real‐time tumor translational and rotational motion were determined from x‐ray images using the KIM technology. A dose reconstruction method was used to evaluate the dose delivered to the target and organs‐at‐risk. Patient‐reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment. Data Format and Usage Notes: The dataset contains planning CT images, treatment plans, structure sets, planned and motion‐included dose‐volume histograms, intrafraction kilovoltage, and megavoltage projection images, tumor translational and rotational motion determined by KIM, tumor motion ground truth data, the linear accelerator trajectory traces, and patient treatment outcomes. The dataset is publicly hosted by the University of Sydney eScholarship Repository at https://doi.org/10.25910/qg5d‐6058. Potential Applications: The 3.6 Tb dataset, with approximately 1 million patient images, could be used for a variety of applications, including the development of real‐time image‐guided methods, adaptation strategies, tumor, and normal tissue control modeling, and prostate‐specific antigen kinetics. [ABSTRACT FROM AUTHOR] |
| Copyright of Medical Physics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Purpose: The US National Institutes of Health state that Sharing of clinical trial data has great potential to accelerate scientific progress and ultimately improve public health by generating better evidence on the safety and effectiveness of therapies for patients (https://www.ncbi.nlm.nih.gov/books/NBK285999/ accessed 2024‐01‐24.). Aligned with this initiative, the Trial Management Committee of the Trans‐Tasman Radiation Oncology Group (TROG) 15.01 Stereotactic Prostate Adaptive Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM) (SPARK) clinical trial supported the public sharing of the clinical trial data. Acquisition and Validation Methods: The data originate from the TROG 15.01 SPARK clinical trial. The SPARK trial was a phase II prospective multi‐institutional clinical trial (NCT02397317). The aim of the SPARK clinical trial was to measure the geometric and dosimetric cancer targeting accuracy achieved with a real‐time image‐guided radiotherapy technology named KIM for 48 prostate cancer patients treated in 5 treatment sessions. During treatment, real‐time tumor translational and rotational motion were determined from x‐ray images using the KIM technology. A dose reconstruction method was used to evaluate the dose delivered to the target and organs‐at‐risk. Patient‐reported outcomes and toxicity data were monitored up to 2 years after the completion of the treatment. Data Format and Usage Notes: The dataset contains planning CT images, treatment plans, structure sets, planned and motion‐included dose‐volume histograms, intrafraction kilovoltage, and megavoltage projection images, tumor translational and rotational motion determined by KIM, tumor motion ground truth data, the linear accelerator trajectory traces, and patient treatment outcomes. The dataset is publicly hosted by the University of Sydney eScholarship Repository at https://doi.org/10.25910/qg5d‐6058. Potential Applications: The 3.6 Tb dataset, with approximately 1 million patient images, could be used for a variety of applications, including the development of real‐time image‐guided methods, adaptation strategies, tumor, and normal tissue control modeling, and prostate‐specific antigen kinetics. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00942405 |
| DOI: | 10.1002/mp.17529 |
